See more : ImpediMed Limited (IPDQF) Income Statement Analysis – Financial Results
Complete financial analysis of Advicenne S.A. (ALDVI.PA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Advicenne S.A., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Infrastructure Materials Corp. (IFAM) Income Statement Analysis – Financial Results
- PT Distribusi Voucher Nusantara Tbk (DIVA.JK) Income Statement Analysis – Financial Results
- Energisa S.A. (ENGI3.SA) Income Statement Analysis – Financial Results
- Generic Gold Corp. (GGC.CN) Income Statement Analysis – Financial Results
- RediShred Capital Corp. (RDCPF) Income Statement Analysis – Financial Results
Advicenne S.A. (ALDVI.PA)
About Advicenne S.A.
Advicenne S.A., a specialty pharmaceutical company, develops and commercializes treatments for nephrology. Its lead product candidate is Sibnayal for the treatment of distal renal tubular acidosis, as well as for the treatment of cystinuria. Advicenne S.A. was founded in 2007 and is headquartered in Paris, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.15M | 2.40M | 2.69M | 2.06M | 2.00M | 1.19M | 806.31K | 268.00K | 109.00K | 1.85M |
| Cost of Revenue | 1.73M | 1.12M | 973.00K | 886.00K | 12.85M | 8.46M | 4.45M | 99.00K | 44.00K | 2.28M |
| Gross Profit | 1.43M | 1.28M | 1.72M | 1.18M | -10.85M | -7.27M | -3.65M | 169.00K | 65.00K | -433.19K |
| Gross Profit Ratio | 45.26% | 53.40% | 63.82% | 57.03% | -542.73% | -610.76% | -452.39% | 63.06% | 59.63% | -23.44% |
| Research & Development | 3.75M | 7.08M | 8.96M | 8.15M | 7.64M | 7.13M | 4.96M | 80.00K | 80.00K | 0.00 |
| General & Administrative | 3.38M | 3.81M | 3.99M | 5.52M | 3.40M | 0.00 | 7.05M | 3.00M | 2.79M | 0.00 |
| Selling & Marketing | 1.08M | 1.07M | 1.57M | 3.83M | 4.01M | 0.00 | 1.50M | 671.00K | 0.00 | 0.00 |
| SG&A | 4.46M | 4.87M | 3.99M | 5.52M | 7.41M | 4.50M | 8.55M | 3.00M | 2.79M | 1.22M |
| Other Expenses | -332.00K | -611.00K | 1.21M | 1.65M | 3.80M | -1.58M | 1.80M | 255.00K | 638.00K | 0.00 |
| Operating Expenses | 7.88M | 11.34M | 14.16M | 15.31M | 3.80M | -1.58M | 1.80M | 3.34M | 3.51M | 2.05M |
| Cost & Expenses | 9.61M | 12.46M | 15.13M | 16.20M | 16.65M | 6.87M | 6.25M | 3.44M | 3.55M | 4.33M |
| Interest Income | 3.00K | 762.00K | 139.00K | 85.00K | 52.36K | 18.35K | 0.00 | 0.00 | 3.00K | 0.00 |
| Interest Expense | 577.00K | 1.37M | 148.00K | 553.00K | 6.18K | 10.42K | 69.16K | 406.00K | 164.00K | 0.00 |
| Depreciation & Amortization | 218.00K | 418.00K | 434.00K | 424.00K | 237.00K | 114.00K | 186.00K | 99.00K | 100.00K | 727.35K |
| EBITDA | -6.24M | -9.87M | -12.04M | -13.98M | -14.01M | -4.97M | -5.05M | -3.55M | -3.79M | -1.77M |
| EBITDA Ratio | -198.16% | -405.80% | -446.89% | -677.74% | -700.70% | -414.11% | -626.23% | -1,144.40% | -3,068.81% | -95.67% |
| Operating Income | -6.46M | -10.06M | -12.44M | -14.14M | -14.63M | -5.63M | -5.44M | -3.17M | -3.45M | -2.50M |
| Operating Income Ratio | -204.92% | -419.65% | -462.74% | -685.50% | -731.65% | -473.07% | -675.22% | -1,182.09% | -3,160.55% | -135.03% |
| Total Other Income/Expenses | -575.00K | -1.37M | 6.00K | -681.00K | 50.00K | 183.48K | -71.79K | -406.00K | -161.00K | 44.41K |
| Income Before Tax | -7.03M | -11.43M | -12.44M | -14.82M | -14.57M | -5.45M | -5.52M | -3.57M | -3.61M | -2.45M |
| Income Before Tax Ratio | -223.17% | -477.01% | -462.55% | -718.57% | -728.79% | -457.65% | -684.12% | -1,333.58% | -3,310.09% | -132.63% |
| Income Tax Expense | -1.00K | 37.00K | -11.00K | 29.00K | -850.68K | -820.71K | -861.42K | 406.00K | 163.00K | 460.32K |
| Net Income | -7.03M | -11.47M | -12.43M | -14.85M | -13.72M | -4.63M | -4.65M | -3.98M | -3.77M | -1.99M |
| Net Income Ratio | -223.14% | -478.56% | -462.14% | -719.98% | -686.24% | -388.68% | -577.29% | -1,485.07% | -3,459.63% | -107.72% |
| EPS | -0.67 | -1.13 | -1.32 | -1.69 | -1.61 | -0.58 | -0.78 | -0.62 | -0.59 | -0.31 |
| EPS Diluted | -0.67 | -1.13 | -1.32 | -1.69 | -1.61 | -0.58 | -0.77 | -0.62 | -0.59 | -0.25 |
| Weighted Avg Shares Out | 10.49M | 10.11M | 9.45M | 8.76M | 8.55M | 7.97M | 5.99M | 6.39M | 6.39M | 6.39M |
| Weighted Avg Shares Out (Dil) | 10.49M | 10.11M | 9.45M | 8.76M | 8.55M | 7.97M | 6.01M | 6.39M | 6.39M | 8.00M |
No news found for: ALDVI.PA
Source: https://incomestatements.info
Category: Stock Reports